Home > Boards > US Listed > Biotechs > Akari Therapeutics (AKTX)

Dr Raymond Prudo Executive Chairman Akari Therapeutics Plc 75 Wimpole Street,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Rogerthat1 Member Profile
 
Followed By 44
Posts 5,565
Boards Moderated 0
Alias Born 04/03/14
160x600 placeholder
Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire Inc. - 11/4/2019 8:33:48 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 10/28/2019 6:01:19 AM
Securities Registration (foreign Private Issuer) (f-1) Edgar (US Regulatory) - 10/15/2019 5:24:28 PM
Securities Registration (ads, Immediate) (f-6ef) Edgar (US Regulatory) - 10/15/2019 5:09:46 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/15/2019 7:08:47 AM
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial R... GlobeNewswire Inc. - 10/14/2019 8:37:28 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 10/10/2019 9:03:34 AM
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th... GlobeNewswire Inc. - 10/10/2019 8:45:02 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 10/4/2019 4:48:17 PM
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference GlobeNewswire Inc. - 9/18/2019 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/13/2019 8:17:32 AM
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid GlobeNewswire Inc. - 9/13/2019 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 9/10/2019 8:22:04 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/9/2019 6:01:20 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 9/6/2019 5:08:04 PM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/6/2019 6:01:28 AM
Akari Therapeutics to Participate in Citi and H.C. Wainwright Conferences in Early September GlobeNewswire Inc. - 9/3/2019 7:00:00 AM
Securities Registration (foreign Private Issuer) (f-1/a) Edgar (US Regulatory) - 8/30/2019 4:04:38 PM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 8/30/2019 4:02:20 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/30/2019 8:13:13 AM
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Hematopoietic Stem Cell Transplantation-Associated T... GlobeNewswire Inc. - 8/30/2019 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/29/2019 8:29:12 AM
Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress GlobeNewswire Inc. - 8/29/2019 8:06:18 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 8/19/2019 4:05:56 PM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 8/14/2019 8:01:05 AM
Rogerthat1   Thursday, 08/16/18 10:17:35 PM
Re: BrazenBull post# 208
Post # of 474 
Dr Raymond Prudo
Executive Chairman
Akari Therapeutics Plc
75 Wimpole Street, London, W1G 9RT

Tel +44 (0) 20 3865 7798

Email ray.prudo@akaritx.com
PA anjala.aoulik@akaritx.com
Web www.akaritx.com

New York office
Akari Therapeutics Plc
24 W 40th Street, 8th Floor
New York, NY 10018

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist